CytoSorbents Corporation is a U.S. medical device company focused on treating life-threatening conditions in the ICU and cardiac surgery using blood purification. The company's flagship product, CytoSorb®, is a blood purification cartridge approved in the European Union and distributed in 75 countries around the world to reduce cytokines and 'cytokine storm' that can cause massive inflammation, organ failure, and death in common critical illnesses.

CytoSorb® therapy for Liver and Kidney

CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based company involved in the R&D and commercialization of medical devices using its proprietary polymer adsorption technology. CytoSorbents is a leader in the treatment of life-threatening conditions in the ICU and cardiac surgery using blood purification.  Its flagship product, CytoSorb®, is distributed in more than 70 countries and has CE Mark approval in the EU for cytokine, bilirubin and myoglobin removal in numerous critical care applications and the removal of ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorbents has multiple active, clinical trials ongoing, including two pivotal randomized, controlled trials in the United States designed to support eventual FDA marketing approval for antithrombotic removal during cardiothoracic surgery using the DrugSorb™-ATR Antithrombotic Removal System.

U.S. Army Medical Research & Development Command

U.S. Department of Defense

Bridge Bank

CytoSorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

COM:CYTOSORBENTS

CytoSorbents Corporation

Last Close

0.89

22/11 21:00

Market Cap

50.31M

Beta: -

Volume Today

76.86K

Avg: -

Analysis Not Available